BioCryst to shut internal drug discovery and close Alabama research site
read at Endpoints ↗Negative
BioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts.
The company said it will seek future programs through external collaborations rather than in‑house research.
As part of the shift, BioCryst will close its research facility in Alabama, ending the site’s operations.
The change reflects a strategic pivot to focus resources on existing pipelines and partnerships.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BioCryst ends internal discovery programs, will close Alabama research facility”
read at Endpoints ↗81 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that